Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 102 participants.
Also called NCT07134712
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 102 participants
- Sponsor
- HONYA Medical Co Ltd
- Registry
-
NCT07134712
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Taiwan
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07134712. Randomized; single masking; primary purpose treatment. Start 2026-03-30 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II
- Acronym
- SEMIAMI
- Condition
- Acute Myocardial Infarction (AMI)
- Intervention (Biological)
- Cord Blood Nucleated cells
- Lead sponsor
- HONYA Medical Co Ltd
Record details
- Record id
cardio:ct-nct07134712- Content hash
8f4b7ee3b8576478a19a20e59358fe3705be5b4c697c3ad5422eba92fdca2fa7